Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
922
datasets available to search
ShareScore release 0.9.0
Dataset results
922 results for “Chronic lymphocytic leukemia”
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
ClinicalTrials.gov study NCT01109069. IPD Sharing: Not stated. Countries: 1. Publications: 3.
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
ClinicalTrials.gov study NCT03406156. IPD Sharing: YES. Countries: 1. Publications: 0.
Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT00267059. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
ClinicalTrials.gov study NCT03624036. IPD Sharing: NO. Countries: 2. Publications: 1.
Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
ClinicalTrials.gov study NCT00262743. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
ClinicalTrials.gov study NCT02303392. IPD Sharing: NO. Countries: 1. Publications: 1.
Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy
ClinicalTrials.gov study NCT00727415. IPD Sharing: NO. Countries: 1. Publications: 1.
Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
ClinicalTrials.gov study NCT00060424. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
ClinicalTrials.gov study NCT00562328. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
ClinicalTrials.gov study NCT02733042. IPD Sharing: Not stated. Countries: 7. Publications: 1.
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
ClinicalTrials.gov study NCT00077922. IPD Sharing: NO. Countries: 1. Publications: 3.
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
ClinicalTrials.gov study NCT02427451. IPD Sharing: NO. Countries: 1. Publications: 3.
Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia
ClinicalTrials.gov study NCT01188681. IPD Sharing: NO. Countries: 5. Publications: 1.
A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT02005471. IPD Sharing: YES. Countries: 20. Publications: 7.
Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
ClinicalTrials.gov study NCT01865617. IPD Sharing: NO. Countries: 1. Publications: 11.
A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT00545714. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
ClinicalTrials.gov study NCT01905943. IPD Sharing: Not stated. Countries: 31. Publications: 3.
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
ClinicalTrials.gov study NCT00098670. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
ClinicalTrials.gov study NCT01578707. IPD Sharing: Not stated. Countries: 10. Publications: 9.
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lym
ClinicalTrials.gov study NCT03462719. IPD Sharing: Not stated. Countries: 14. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.